Vascular Impact of Cancer Therapies: The Case ... - CLL Support
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
You need to be a member of this community to see this post.
Read more about...
- Counselling
- Aspirin
- Clinical trials
- Chemotherapy
- Ibrutinib
- Anticoagulants
- Venetoclax
- Tyrosine
- Trastuzumab
- Vitamin E
- Obinutuzumab
- Percutaneous coronary intervention
- NSAIDs
7 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
Managing the cardiovascular risk of Bruton's Tyrosine Kinase Inhibitors in chronic lymphocytic leukemia
The American Society of Hematology journal Blood Advances published an important...
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
August 16, 2020
Fewer off-target effects mean second-generation BTK inhibitors offer less...
A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor
How does zanubrutinib differ from ibrutinib in pharmacokinetics and target occupancy?
Zanubrutinib...
Related Posts
CAR-T for CLL Hits Goal of Mid-Stage Trial - All patients had progressed on BTK inhibitors & most had failed venetoclax - MedPageToday, 6/12
Clemastine (Tavegyl), an over-the-counter drug, found to be effective at inducing LMP and cell death
The possible efficacy of BTK inhibitors lessening the effects of COVID-19
Ibrutinib Slow but steady foreward movement.- BTK Degrader Shows Potential for Treating Refractory CLL and SLL
